(NASDAQ: CGEN) Compugen's forecast annual revenue growth rate of -17.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Compugen's revenue in 2026 is $72,764,000.On average, 8 Wall Street analysts forecast CGEN's revenue for 2026 to be $1,780,436,587, with the lowest CGEN revenue forecast at $926,621,272, and the highest CGEN revenue forecast at $2,978,425,517. On average, 8 Wall Street analysts forecast CGEN's revenue for 2027 to be $3,117,418,707, with the lowest CGEN revenue forecast at $518,907,912, and the highest CGEN revenue forecast at $4,964,042,528.
In 2028, CGEN is forecast to generate $3,676,228,066 in revenue, with the lowest revenue forecast at $2,501,877,434 and the highest revenue forecast at $5,050,275,038.